Garuda - Garba Rujukan Digital

p-Index From 2021 - 2026

2.693

P-Index

This Author published in this journals

All Journal Indonesian Journal of Pharmaceutical Science and Technology Jurnal Farmasi Klinik Indonesia INDONESIAN JOURNAL OF PHARMACY Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Jurnal Penelitian Pendidikan IPA (JPPIPA) Jurnal Pengabdian Pada Masyarakat Window of Health : Jurnal Kesehatan JFIOnline JURNAL MEDIA KESEHATAN Majalah Farmasetika Indian Journal of Forensic Medicine & Toxicology Folia Medica Indonesiana

Budi Suprapti

Department Of Pharmacy Practice, Faculty Of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

Author-ID : 393630

Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Computer Science & IT Decision Sciences, Operations Research & Management Education Engineering Health Professions Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Other

Published : 33 Documents Claim Missing Document

Claim Missing Document

Articles

Title

Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1 Suprapti, Budi; Hartono, Frenky; Iqbal, Muhammad; Zuhri, Muhammad Isnaini; Aditiawardana, Aditiawardana
Indonesian Journal of Pharmacy Vol 30 No 1, 2019
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Chronic kidney disease (CKD) lead to secondary hyperparathyroidism (sHPT) that caused by phosphate retention and hypocalcemia. This condition known as mineral and bone disorder (CKD-MBD). The increase in parathyroid hormone would increase bone turnover that result in an increased risk of bone fractures, and vascular calcification. These will increase the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), and bone-specific alkaline phosphatase (b-ALP), which is a marker of bone turnover, and also dickkopf-related protein 1 (DKK-1), which is an inhibitor of the Wnt pathway. Secondary hyperparathyroidism in CKD also caused by calcitriol deficiency. Paricalcitol is a synthetic calcitrol analogue used to reduce parathyroid hormone (iPTH) with minimal calcemic and phosphatemic activity. Vitamin D receptor activation by paricalcitol will decrease TRAP5b, b-ALP, and DKK-1. In this study we reported 9 cases of CKD-MBD with Hemodialysis (HD) and associated with sHPT. Four of nine cases received 5μg paricalcitol every HD (twice a week) while the others five is not. Level of iPTH, phosphate, calcium, TRAP5b, b-ALP, and DKK-1 were measured before initiation of study and after three months treatment. According to this study, the paricalcol administration suppresses the increase in iPTH level, bone turnover and vascular calcification showed by decreasing or supresses the increase b-ALP, TRAP5b, DKK-1 leves without increasing calcium and phosphate levels.

Review of Insulin Therapy In Type 2 Diabetes Mellitus Ambulatory Patients Budi Suprapti; Nia Widyasari; Mahardian Rahmadi; Cahyo Wibisono
Indonesian Journal of Pharmacy Vol 28 No 4, 2017
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

The purposes of this study were to review utilization of insulin therapy in type 2 diabetes mellitus out patients and identify its drug related problems. The data were collected cross-sectionally with purposive sampling method in the period March 2016 until May 2016 in Outpatient Clinic Universitas Airlangga Teaching Hospital Surabaya. The results of 240 patients showed that insulin was used as monotherapy insulin in 2,9% patients; combination 1 insulin & 1-4 OAD in 31,3%; basal bolus therapy 27,9%; combination basal−bolus therapy & 1-3 OAD 43,9%. Based on blood glucose target achievement, only 20,8% of patients achieve the target, 75,1% failed to achieve the target and 4,1% suffered from hypoglycemia. Drug related problems identified adverse drug reaction of antidiabetic therapy such as hypoglycemia (6.7%), nausea (3.8%), bloating (1.3%), increase of flatulency (2.9%) and inappropriate combination (0,4%). In conclusion insulin therapy was complicated and individually, most of the patients still did not reach the target and there was potential drug related problem in this patients group. So that caring from solid inter-professional health collaboration is needed

Effects of Probiotics and Vitamin B Supplementation on IFN-γ and IL-12 Levels During Intensive Phase Treatment of Tuberculosis Budi Suprapti; Suharjono Suharjono; Rahmawati Raising; Yulistiani Yulistiani; Zamrotul Izzah; Wenny Putri Nilamsari; Prastuti Asta Wulaningrum; Arief Bachtiar
Indonesian Journal of Pharmacy Vol 29 No 2, 2018
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Tuberculosis is an acute infectious disease that primarily affects the lungs. Probiotics supplementation can increase the number and activity of NK cell in peripheral blood by modulation of IL-12, thus increasing IFN-γ production by Th1 response. Vitamin B1 acts on macrophages and affects neutrophil motility. Vitamin B6 is associated with the release of cytokines and the responsiveness of NK cells, while vitamin B12 affects to lymphocytes, Tcell proliferation, CD4+ ratios, and NK cell activity. To analyze the effects of probiotics and vitamin B1, B6, B12 supplementation on IFN-γ and IL-12 levels during intensive phase of antituberculosis treatment. The study was pre-post test randomised control by time series. The control group was TB patients with standard therapy of antituberculosis and vitamin B6, while the intervention group was TB patients receiving therapy plus once daily probiotics and vitamin B1, B6, B12supplementation during the intensive phase. Blood samples were withdrawn at baseline, one month, and two months after therapy to measure plasma IFN-γ and IL-12 levels using the ELISA method. Twenty two patients were divided equally into two groups. There was a tendency to greater increase of IFN-γ in the first month of the intervention group, followed by a significant decline after two-month therapy (p < 0.05). In both groups there was a rise in IL-12 levels after one month followed by a decrease in the second month (p > 0.05). However, the percentage was higher in the supplementation group. Adding probiotics and vitamins B1, B6, B12 could improve immune response through IL-12 and IFN-γ modulation during intensive phase therapy.

BLOOD GLUCOSE TARGET ACHIEVEMENT AND ANTIDIABETES REGIMEN IN TYPE-2 DIABETIC GERIATRIC PATIENTS Budi Suprapti
Indonesian Journal of Pharmacy Vol 25 No 2, 2014
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Diabetes mellitus (DM) is a leading caused morbidity in geriatric patients. The prevalence of type-2 DM is more than 90% of DM population and increase with age, and half of those patients were geriatric. Blood glucose (BG) control is important for prevention diabetes complications, but attention must be given in geriatric patients due to the increasing susceptibility to risk of hypoglycemia. The aimed of this study was to identify BG achievement in diabetic geriatric patients and its therapeutic management. This study was done in Outpatient Geriatric Clinic, Dr. Soetomo General Hospital Surabaya Indonesia in the period of March to June, 2012. The inclusion criteria were type-2 diabetic geriatric patients with/without diabetic complication that received antidiabetic therapy and had BG data. The results from 165 patients showed that BG target achieved by 53% patients, 41% patients not achieved the target, while 6% patients in risk ofhypoglycemia. Management therapy for patients with achieved BG target was done by (1) continued therapy as before, (2) increasing dosage regimen for patients with BG already in the target but still within the upper limit target or decrease dosage regimen for patients with BG in lower limit target to avoid hypoglycemia, (3) change type of medication for patients who experienced side effects. Meanwhile, from all patients that failed to achieve BG target there were some patients received additional medications and regimen changes, but the rest of those didn’t receive any additional medication or regimen changes, which were many of them eventually became one of the drug-related problems in this patient group. In conclusion, there were still quite large number patients that did not achieve BG target, therapy management changes were made based on BG profile and there were drug related problems related to dosage regimen that needs pharmaceutical care intervention

EFFECT OF DIALYZER REUSE UPON UREA REDUCTION RATIO (URR), KT/V UREA AND SERUM ALBUMIN IN REGULAR HEMODIALYSIS PATIENT Ni Made Amelia R. Dewi; Budi Suprapti; I Gde Raka Widiana
Indonesian Journal of Pharmacy Vol 26 No 3, 2015
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Reuse of dialyzers for hemodialysis can help in bringing down the cost of hemodialysis. On the other hand reuse of dialyzer may change dialyzer integrity. This study was undertaken to determine dialyzer reuse effect on Urea Reduction Ratio (URR), Kt/V urea and serum albumin. This was prospective study in Sanglah Public General Hospital Denpasar. Inclusion criteria for this study were patients who receive hemodialysis more than 3 months on twice weekly hemodialysis. In the study we used hollow fiber or dialyzer Elisio type H-130H reprocessed with Renaline automatically by machine renatron. After each session blood urea, post dialysis weight and serum albumin were measured. Measurements was performed on the use new dialyzer, 1st reuse, 4th reuse and 7th reuse. The dialyzer was discarded, if TCV fell below 80% of baseline value. Kt/V and urea reduction ratio (URR) were calculated as measure of dialysis adequacy. A total of 23 people completed the study. There was a lack of uniformity duration of hemodialysis, so that we also performed an analysis using a uniform length hemodialysis duration (4.5 hours) with 15 samples. There were no significant difference between URR and Kt/V urea of new dialyzer and dialyzer reprocessed by renaline respectfully with p=0.131 and p=0.373. If we analyzed only using uniform time of dialysis (4.5 h) the value of URR and Kt/V urea between new and reused dialyzer not significantly different with p=0.520 and p=0.784. There was also not found significant differences between serum albumin of the use new dialyzer and reused dialyzer by the time of uniform or non-uniform, respectfully with p=0.271 and 0.073. Reuse dialyzer does not alter efficacy of hemodialysis.Key words : Dialyzer, Urea Reduction Ratio (URR), Kt/V Urea, Albumin, Total Cell Volume (TCV)

Co-Authors Abdul Rahman Bahmid Aditiawardana Aditiawardana, Aditiawardana Alsagaff, M. Yusuf Andarsari, Mareta R. Aniek S. Budiatin Ardiana, Shafira muti Arfiani, Ria Fitrah Arief Bachtiar Arina Deri Puspita Sari Arina Dery Puspitasari Ayunda Nur Hidayatiningsih Azril O. Ardhiansyah Bella Donna Perdana Putra Budiatin, Aniek S. Bulqiah, Andi Cahyo Wibisono Cahyo Wibisono Nugroho Chrysnanda Maryska Dewi Damayanti Dewi W. Shinta Dewi W. Shinta Dewi Wara Shinta Didik Hasmono Dinda Monika Nusantara Ratri Dinda Monika Nusantara Ratri Eddy Rahardjo Enda Mora Enok Nurliawati Fathia Ramadiani FITRIANI, VICTORIA YULITA Hapsari, Pharmasinta P. Hartono, Frenky Hidayati, Movita I Gde Raka Widiana Idha, Arofa Idha, Arofa Junaidi Khotib Khusnul Fitri Hamidah Kusmiati, Tutik M. Yusuf M. Yusuf Assegaf Mahardian Rahmadi Makmuroh Nurul Qomar Purnamawati, Dewi Mansur, Mifta Marcha Debby Saraswati Marcha Debby Saraswati Marcha Debby Saraswati Mareta R. Andarsari Mareta Rindang Andarsari Meyta Sari, Cinantya Muhammad Amin Mulya Sundari Ni Made Amelia R. Dewi Ni Made Mertaniasih Nia Widyasari Novan Y. I. Pratama Nurmainah Nurmainah Pharmasinta P. Hapsari Pharmasinta Putri Hapsari Prasetya, Anak Agung Ngurah Putra Riana Prasetya, Anak Agung Ngurah Putra Riana Prastuti Asta Wulaningrum Purwiningtyas, Mida Putranto, J.Nugroho Eko Putri Nilamsari, Wenny R.R. Endang Lukitaningsih Raden Mohamad Herdian Bhakti Rahmawati Raising Ramadiani, Fathia Retna Dwi Puspitarini Ritonga, Fany Devita S. Soedarsono Santi, Bayu Dharma Santoso, Agustinus Santoso, Agustinus Sarah Puspita Atmaja Sari, Cinantya Meyta Selvia Febriana Astuti Sensusiati, Anggraini Dwi Shafira Muti Ardiana Shanti, Bayu Dharma Shanti, Bayu Dharma Shinta, Dewi W. Sjamsiah, Siti Sjamsiah, Siti Sofiati Diah Baisuni Subakti Zulkarnain, Bambang Suharjono Suharjono, Suharjono Susilo, Dwi Hari Thomas Erwin Christian Junus Huwae Toetik Aryani UMI FATMAWATI Wahyuni, Diyah WENNY PUTRI NILAMSARI Yosiyanita Safari Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani Yulistiani, Yulistiani Yusuf Alsagaff, Mochamad Zahra Oviary Satryo, Fatimatuz Zamrotul Izzah Zedny Norachuriya Zuhri, Muhammad Isnaini

Title Search

Found 5 Documents Search Journal : INDONESIAN JOURNAL OF PHARMACY

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 5 Documents
Search
Journal : INDONESIAN JOURNAL OF PHARMACY